Cargando…
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Masson SAS.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195369/ https://www.ncbi.nlm.nih.gov/pubmed/32240719 http://dx.doi.org/10.1016/j.medmal.2020.03.006 |
| _version_ | 1783528519361363968 |
|---|---|
| author | Molina, J.M. Delaugerre, C. Le Goff, J. Mela-Lima, B. Ponscarme, D. Goldwirt, L. de Castro, N. |
| author_facet | Molina, J.M. Delaugerre, C. Le Goff, J. Mela-Lima, B. Ponscarme, D. Goldwirt, L. de Castro, N. |
| author_sort | Molina, J.M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7195369 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71953692020-05-02 No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Molina, J.M. Delaugerre, C. Le Goff, J. Mela-Lima, B. Ponscarme, D. Goldwirt, L. de Castro, N. Med Mal Infect Letter to the Editor Elsevier Masson SAS. 2020-06 2020-03-30 /pmc/articles/PMC7195369/ /pubmed/32240719 http://dx.doi.org/10.1016/j.medmal.2020.03.006 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Molina, J.M. Delaugerre, C. Le Goff, J. Mela-Lima, B. Ponscarme, D. Goldwirt, L. de Castro, N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |
| title | No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |
| title_full | No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |
| title_fullStr | No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |
| title_full_unstemmed | No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |
| title_short | No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |
| title_sort | no evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe covid-19 infection |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195369/ https://www.ncbi.nlm.nih.gov/pubmed/32240719 http://dx.doi.org/10.1016/j.medmal.2020.03.006 |
| work_keys_str_mv | AT molinajm noevidenceofrapidantiviralclearanceorclinicalbenefitwiththecombinationofhydroxychloroquineandazithromycininpatientswithseverecovid19infection AT delaugerrec noevidenceofrapidantiviralclearanceorclinicalbenefitwiththecombinationofhydroxychloroquineandazithromycininpatientswithseverecovid19infection AT legoffj noevidenceofrapidantiviralclearanceorclinicalbenefitwiththecombinationofhydroxychloroquineandazithromycininpatientswithseverecovid19infection AT melalimab noevidenceofrapidantiviralclearanceorclinicalbenefitwiththecombinationofhydroxychloroquineandazithromycininpatientswithseverecovid19infection AT ponscarmed noevidenceofrapidantiviralclearanceorclinicalbenefitwiththecombinationofhydroxychloroquineandazithromycininpatientswithseverecovid19infection AT goldwirtl noevidenceofrapidantiviralclearanceorclinicalbenefitwiththecombinationofhydroxychloroquineandazithromycininpatientswithseverecovid19infection AT decastron noevidenceofrapidantiviralclearanceorclinicalbenefitwiththecombinationofhydroxychloroquineandazithromycininpatientswithseverecovid19infection |